First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors
Publication
, Conference
Published in: Journal of the American Academy of Dermatology
May 2016
Duke Scholars
Published In
Journal of the American Academy of Dermatology
DOI
ISSN
0190-9622
Publication Date
May 2016
Volume
74
Issue
5
Start / End Page
AB250 / AB250
Publisher
Elsevier BV
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors. (2016). In Journal of the American Academy of Dermatology (Vol. 74, pp. AB250–AB250). Elsevier BV. https://doi.org/10.1016/j.jaad.2016.02.976
“First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors.” In Journal of the American Academy of Dermatology, 74:AB250–AB250. Elsevier BV, 2016. https://doi.org/10.1016/j.jaad.2016.02.976.
First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors. In: Journal of the American Academy of Dermatology. Elsevier BV; 2016. p. AB250–AB250.
“First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors.” Journal of the American Academy of Dermatology, vol. 74, no. 5, Elsevier BV, 2016, pp. AB250–AB250. Crossref, doi:10.1016/j.jaad.2016.02.976.
First line biologic agent therapy for moderate-to-severe psoriasis in cancer survivors. Journal of the American Academy of Dermatology. Elsevier BV; 2016. p. AB250–AB250.
Published In
Journal of the American Academy of Dermatology
DOI
ISSN
0190-9622
Publication Date
May 2016
Volume
74
Issue
5
Start / End Page
AB250 / AB250
Publisher
Elsevier BV
Related Subject Headings
- Dermatology & Venereal Diseases
- 3202 Clinical sciences
- 1103 Clinical Sciences